Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Quantum Biopharma ( (TSE:QNTM) ).
On July 8, 2025, Quantum BioPharma Ltd. announced the submission of its patented drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program. This submission marks a significant step in accelerating the clinical development and regulatory approval process for this first-in-class treatment for multiple sclerosis. The ILAP program aims to expedite the delivery of groundbreaking treatments to patients, potentially enhancing Quantum BioPharma’s market position and providing early access to new medical innovations for patients in the UK.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of its lead compound, Lucid-MS, which targets multiple sclerosis by preventing and reversing myelin degradation. Quantum BioPharma also has strategic investments and retains a significant ownership stake in Unbuzzd Wellness Inc., a company focused on over-the-counter products.
Average Trading Volume: 7,823
Technical Sentiment Signal: Hold
Current Market Cap: C$64.69M
Find detailed analytics on QNTM stock on TipRanks’ Stock Analysis page.